|Chemical and physical data|
|Molar mass||357.530 g/mol|
|3D model (JSmol)|
Tonazocine (WIN-42,156) is an opioid analgesic of the benzomorphan family which made it to phase II clinical trials for the treatment of postoperative pain, but development was apparently ceased and ultimately it was never marketed. Tonazocine is a partial agonist at both the mu-opioid and delta-opioid receptors, but acting more like an antagonist at the former and more like an agonist at the latter. It lacks most of the side effects of other opioids such as adverse effects on the cardiovascular system and respiratory depression, but it can cause sedation (although to a lesser degree of typical opioids), and in some patients it may induce hallucinations (probably via binding to and activating the κ-opioid receptor).
- American Chemical Society. Division of Medicinal Chemistry (1990). Annual Reports in Medicinal Chemistry. Academic Press. p. 12. ISBN 978-0-12-040525-1. Retrieved 30 November 2011.
- Ward SJ, Pierson AK, Michne WF (February 1985). "Pharmacological profiles of tonazocine (Win 42156) and zenazocine (Win 42964)". Neuropeptides. 5 (4-6): 375–8. doi:10.1016/0143-4179(85)90032-0. PMID 2860595.
- Hudzik TJ, Howell A, Payza K, Cross AJ (May 2000). "Antiparkinson potential of delta-opioid receptor agonists". European Journal of Pharmacology. 396 (2-3): 101–7. doi:10.1016/S0014-2999(00)00209-0. PMID 10822062.
- Aronson, Jeffrey K. (30 November 2009). Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs. Elsevier. p. 154. ISBN 978-0-444-53273-2. Retrieved 30 November 2011.
See also: Receptor/signaling modulators • Signaling peptide/protein receptor modulators